Screener
bioAffinity Technologies, Inc. BIAF Q3 2026 earnings
Reported November 6, 2026 · After market close
Revenue$1.1MMiss by $834.7K
EPS-$5.89Beat by $25.61
Revenue estimate$1.9M
EPS estimate-$31.50
“Our third-quarter results reflect CyPath Lung's continued momentum in addressing the critical need for early lung cancer detection, driven by both new physicians ordering the test and increased use by existing customers. We believe this growth reflects increasing physician engagement and recognition of the role CyPath Lung can play in managing care for patients at risk for lung cancer. We are also advancing its potential use in surveillance following curative-intent treatment, where CyPath Lung could complement imaging in monitoring for recurrence and new cancers”
Next report
Date not yet announcedVersus estimates
Revenue
Diluted EPS
FAQ
- When did bioAffinity Technologies, Inc. report Q3 2026 earnings?
- bioAffinity Technologies, Inc. (BIAF) reported Q3 2026 earnings on November 6, 2026 after market close.
- What were bioAffinity Technologies, Inc.'s Q3 2026 revenue and EPS?
- bioAffinity Technologies, Inc. reported revenue of $1.1M and eps of $-5.89 for Q3 2026.
- Did bioAffinity Technologies, Inc. beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $1.9M by $834.7K. EPS beat the consensus estimate of $-31.50 by $25.61.
- How did bioAffinity Technologies, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 26.0% from $1.4M a year earlier and eps declined 118.1% from $-2.70.
- Where can I find bioAffinity Technologies, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001493152-26-050541) and the 10-Q periodic report (0001493152-26-050540) directly on SEC EDGAR. The filing index links above go to sec.gov.
